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Cytochrome P450 metabolizes many drugs in the liver. Three genotypes of CYP2C19 with extensive, intermediate,
and poor metabolizing activity, respectively, have been identified in peripheral blood of transplant recipients and
new liver grafts in living donor liver transplantation (LDLT). The expression of the final genotype in liver graft
biopsies depends on the donor, whereas the expression in peripheral blood mononuclear cells depends on the
recipient. The metabolizing isoenzyme of the major anti-rejection agents passes through CYP3A4, CYP3A5 and
MDR1, which have also been identified to have similar biological characteristics as genotype of CYP2C19 in liver
tissue. Recently, pyrosequencing has been used to investigate the expressions of different genotypes in liver grafts
in LDLT. This review focuses on recent findings regarding the biological expressions of the CYP2C19, CYP3A4,
CYP3A5 and MRD1 genotypes in liver grafts before and after LDLT. The application of pyrosequencing may be
beneficial in further research on liver transplantation. Laser capture microdissection of hepatocytes in liver grafts
may be a direction for future research.
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Homogenous phenomenonCore tip
The genotypic expressions of CYP2C19, CYP3A4,
CYP3A5 and MDR1 contribute to the mainstream by
donor liver grafts in living donor liver transplantation.
Pyrosequencing can identify homogenous phenomenon
when different genotype expressions are found between
the donor and recipient. These findings can help trans-
plant hepatologists and those in the field of organ trans-
plantation to understand how drug metabolism modifies
cytochrome P450 in a new graft after liver transplantation.Introduction
Cytochrome P450 contain isoenzymes which metabolize
many drugs in the liver [1]. To understand this compli-
cated system, CYP2C19 and its genotypes can be used
to describe the characteristics of the isoenzymes in
cytochrome P450. CYP2C19 is one of the important* Correspondence: c471026@ms6.hinet.net
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unless otherwise stated.isoenzymes responsible for drug metabolism including
anti-convulsant and antacid agents [2, 3]. Based on
the metabolic rate of a drug, there are three genotypes
including extensive metabolizer (homozygous extensive
metabolizer, HomEM), intermediate metabolizer (het-
erozygous extensive metabolizer, HetEM) and poor
metabolizer (PM). The distribution of each differs de-
pending on ethnicity. We previously identified that PM
accounts for about 13.3 to 16.7 % of cases in Taiwan [4,
5]. In liver transplant recipients with the PM CYP2C19
genotype, lower doses of proton-pump inhibitors can
be used to avoid drug intoxication in the treatment of
peptic ulcer disease [6]. However, changes in the geno-
type in recipients and donors such as HomEM to PM
or PM to HetEM in the setting of living donor liver
transplantation (LDLT) have yet to be elucidated. This
review focuses on our recent reports to investigate the
isoenzymes that are modified by cytochrome P450
after LDLT.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CYP2C19
CYP2C19 is one of the polymorphic isoenzymes in the
cytochrome P450 system that is responsible for the me-
tabolism of several therapeutically important drugs
such as proton-pump inhibitors including omeprazole,
lansoprazole and pantoprazole [7]. Because of the im-
pact on drug metabolism, CYP2C19 may be important
in LDLT. We previously used DNA extraction and
polymerase chain reaction (PCR) to amplify DNA with
all six fragments of the CYP2C19 gene corresponding
to exon 1 (406 bp), 2–3 (606 bp), 4 (271 bp), 5 (409 bp),
7 (325 bp), and 9 (529 bp). Genomic DNA was isolated
from the peripheral blood mononuclear cells of donors
and recipients, and the CYP2C19 polymorphisms were
identified. HomEM had wild-type alleles (*1/*1), HetEM
had one mutated allele (*1/*2 or *1/*3), and PM had
homozygous mutations (m1 in exon 5 or m2 in exon 4) of
CYP2C19 (*2/*2, *3/*3 or *2/*3). Although the genotypes
of CYP2C19 were different between the donors and re-
cipients before LDLT, the original genotype expressions
in the peripheral blood of the recipients did not affect
the CYP2C19 genotypes of the donor liver grafts with
different allelic patterns after LDLT [4].
In fact, the liver enzymes were easily detected early
after LDLT, and the one of the important concerns was
acute rejection. The incidence of acute rejection was
12.9–15.0 % in our earlier reports [5, 8]. When elevated
liver enzymes are noted within 1 month after liver trans-
plantation and the ratio of aspartate transferase/alanine
transferase (AST/ALT) is less than 1.0, it should be con-
sidered an episode of acute rejection [8]. Many interest-
ing findings have been reported when the genotypes of
CYP2C19 have been applied to abnormal liver enzymes
after LDLT. For example, the incidence of abnormal liver
enzymes has been reported to be higher with CYP2C19
genotype HomEM (84.2 %) than HetEM (51.5 %) and
PM (16.7 %), with a linear trend relationship [5]. Logistic
regression analysis showed that the higher risk estimate
of abnormal liver enzymes with HomEM was 26.7 times
that of PM and HomEM 5 times that of PM [5]. This
suggests that recipients with the HomEM CYP2C19
genotype may have a higher ability to metabolize drugs
and therefore require a higher dose of immunosuppres-
sion agents after LDLT.
Percutaneous liver biopsies are performed when clinic-
ally required after LDLT. The polymorphisms of CYP2C19
found in liver tissue depends on the liver graft of the
donor, even if the genotype is different between the recipi-
ent and donor. Western blotting can be used to identify
the genotype, however the reason for the discrepancies
between extensive and poor metabolizers in CYP2C19
after LDLT have yet to be explained [9]. In our previous
study, direct sequencing of CYP2C19 genotypes showedthat the sequence of graft liver CYP2C19 at exon 5
(681G > A) expressed a mixed pattern but was finally
similar to that of the donor after LDLT. We named this
morphological change the homogenous phenomenon
[10] as shown in Fig. 1. Although the peripheral blood
continuously flows through the liver graft, the effect on
genotype expression from the recipient was limited. In
DNA sequencing, the final presentation of CYP2C19
polymorphisms of the liver graft fully expressed the
genotyping characteristic arising from the donor with
limited morphological changes. In a donor with the
CYP2C19 genotype PM (m1 in exon 5, 681A, *2/*2) and
a recipient with HetEM (681 A/G, *1/*2) LDLT, follow-
up liver biopsies showed a mixed pattern of CYP2C19
sequencing with a similar wave pattern but smaller
amplitude than that of the donor [10]. It is known that
the major anti-rejection agents such as cyclosporine A
and tacrolimus are metabolized through cytochrome
P450 with isoenzymes CYP3A4, CYP3A5 and multiple
drug resistant 1 (MDR1), however CYP2C19 may not be
involved with those agents. Therefore, we performed
further research on CYP3A4, CYP3A5 and MDR1.
CYP3A5
CYP3A5 is one of the most important isoenzymes for
the metabolism of anti-rejection agents in cytochrome
P450. Different from CYP2C19, CYP3A5 does not have
any other genotypes. The morphological pattern did not
present a significant quantitative expression in direct
DNA sequencing or Western blotting. Investigations of
CYP3A5*3 haplotypes with A/A, A/G and G/G genotypes
may lead to a better understanding of the possible
homogenous phenomenon in LDLT. We used PCR assays
with the forward primer 5′-CATGACTTAGTAGACA-
GATGAC-3′ and reverse primer 5′-GGTCCAAACAGG-
GAAGAAATA-3′, and PCR with restriction fragment
length polymorphism (PCR-RFLP) to explore the positions
of CYP3A5 polymorphisms at rs776746 and identified the
haplotypes of a single nucleotide polymorphism (SNP).
The CYP3A5 *1/*1 genotype showed bands of 148, 125
and 20 bp in length, and the CYP3A5 *3/*3 genotype
showed bands of 168 and 125 bp in length [11].
Pyrosequencing was performed with PyroMark Assay
Design Software 2.0, and PCR assays were prepared with
a PyroMark PCR Kit (Qiagen). The biotinylated forward
primer 5′-TGTACCACCCAGCTTAACGA-3′ and a
reverse primer at the 5′ end (5′-GGTCCAAACAGG-
GAAGAAAT-3′) were applied. The biotinylated PCR
products were analyzed and expressed with propor-
tional haplotyping of CYP3A5*3 from the peripheral
blood and liver graft biopsy tissue of the recipients who
underwent LDLT [11]. This method allowed for the
objective investigation of the proportions of A/A, A/G
and G/G and comparisons before and after LDLT on
Fig. 1 Picture of the homogenous phenomenon arising from the different genotypes of CYP2C19, CYP3A4, CYP3A5 and MDR1 between the
donor and recipient in the cytochrome P450 system after living donor liver transplantation. The homogenous phenomenon is representing with
the recipient blood (green block) go in the liver graft (white color) but the black ground of cytochrome P450 is still remain their own characteristic of
isoenzymes even the recipient blood go through the graft
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document the products belonging to A/G or G/G when
an unusual interpretation was noted in pyrosequencing.
According to pyrosequencing of the CYP3A5*3 genotypes,
the homogenous phenomenon could be identified in the
liver graft of the recipient after LDLT. This suggests that
the final expression of CYP3A5*3 in liver grafts is truly
dependent on the donor with only a limited change in
the recipient. This biogenetic effect could potentially be
predicted before LDLT in the screening stage of liver
donation.
CYP3A4
Similar to the CYP3A family, CYP3A4*18 could be easily
identified with PCR-RFLP for DNA sequencing as with
CYP3A5*3. A different primer for the PCR assay was
used with a forward primer 5′-CACCCTGATGTCCAG-
CAGAAA CT-3′ and reverse primer 5′-AATAGAAAG-
CAGATGAACCAGAGCC-3′. The probe was prepared
with 5′-TTTTTTTTTTTTTTT TTTTTTTTTACCTC
CTCCCTCCTTCTCCATGTAC-3′ for CYP3A4*18-G and
5′-TTTTTTTTTTTTTTTTTTTTTTACCTCCTCCCTC
CTTCTCC ATGTAT-3′ for CYP3A4*18-A [12]. Based on
the haplotypes of the SNP from PCR-RFLP, three poly-
morphism genotypes were expressed as T/T, T/C and C/C
by CYP3A4*18. CYP3A4 is an important isoenzyme in
cytochrome P450 in liver and renal transplantation. Par-
ticular attention to the role of CYP3A4 when using
anti-fungal agents such as ketoconazole concomitantly
with anti-rejection drugs such as tacrolimus should be
paid as this can cause severe pharmacokinetic drug todrug interactions [13–15]. In the CYP3A4*18 genotyping
pyrosequence of the liver graft biopsies, the homogenous
phenomenon was identified with the CYP3A4*18 SNP
with the wild-type T allele and mutant variant C allele of
the liver grafts, which arose from the donor and was
different from the peripheral blood of the recipient after
LDLT. The clinical implication is that recipients may be
need a high dose of tacrolimus due to the extensive me-
tabolism of the potential donor expressing CYP2C19
HomEM and CYP3A4*18 exon 10 wild-type 878 T > C/T
after liver transplantation.
MDR1
Transporter proteins (MDR1, gene coding glycoprotein-P,
P-gp, ABCB1 gene) impact the required dose of anti-
rejection organ transplantation agents such as tacrolimus
and cyclosporine A due to pharmacokinetics. MDR1-3435
is a common polymorphism involved in both the
pharmacokinetics and pharmacodynamics in LDLT. We
used PCR-RFLP to explore genotype exon 26 C3435T
variant alleles in MDR1, and PCR assays using the
forward primer 5′-TGCTGGTCCTGAAGTTGATCTG
TGAAC-3′ and reverse primer 5′-ACATTAGGCAGT-
GACTCGATGAAGGCA-3′. The PCR product was
digested with Sau3A I. In the pyrosequencing expres-
sion of the SNP, the C allele was the wild-type, and the
T allele was the mutant variant of MDR1-3435. The
homogenous phenomenon was also identified in the
difference between the liver graft and the peripheral
blood of the recipients in C > C/T, C/T > C, C/T > T
and T > C/T, but was similar to those of the donors
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drug-metabolizing enzymes was found to be different
from the donor, and a homogenous phenomenon was
identified. However, changes in isoenzyme polymor-
phisms in the liver grafts were not manifested in the
peripheral blood. Therefore, to understand the correl-
ation of genes in liver grafts after liver transplantation
when liver graft biopsy tissue is available from the
recipient, the drug concentration in the blood is im-
portant, however examinations of the donor blood can
further reveal the association between the liver graft
and recipient after LDLT. It is difficult to know whether
anti-rejection agent metabolism occurs through the
isoenzymes of the liver graft, or whether it is related to
intestinal isoenzymes. Small expressions of intestinal
isoenzymes have been reported [17–19]. In our recent re-
port, we investigated the relationship between CYP2C19
and CYP3A4*18, CYP3A5*3, and MDR1-3435. None of
the haplotypes of these isoenzymes had a significant dif-
ference on the proportional distribution [16]. In other
studies, liver graft hepatocytes were isolated using laser
capture microdissection [20–22]. Interestingly, two dif-
ferent genotypes of isoenzymes were identified in the
cytochrome P450 system, one arising from the donor
liver and the other originating from the recipient’s cir-
culating blood. The drugs passing through the common
polymorphism may impact both the pharmacokinetics
and pharmacodynamics. Finally, acute rejection usually
occurs within one month after liver transplantation, and
the homogenous phenomenon may play a role in the
slowdown of acute rejection after LDLT. Our findings
also suggest that intestinal isoenzymes play a compensa-
tory role within one month after liver transplantation
[13, 23]. With time, the coordinator role of the different
genotypes creates a homogenous phenomenon to adjust
the anti-rejection agents. Therefore, acute rejection should
be resolution about one month after LDLT [24, 25].
In other words, CYP2C19 is one of the common isoen-
zymes of cytochrome P450 in the field of the gastroenter-
ology for the proton pump inhibitor metabolism. The
characteristic of different metabolism is believable treat-
ment guide line by the gastroenterologists in clinical prac-
tice. In our recent reports, the genotypes of CYP2C19
could be modified by the donor graft not only on the drug
metabolism for the peptic ulcer, but also possible on the
immunosuppression agent causing abnormal liver function
at the first month after LDLT. It may be play a major role
to the monitoring of the drug metabolism in immunosup-
pression effect. We step-by-step to study more and more
isoenzymes related to the field of the liver transplantation
and discovery the evidence of homogenous phenomenon
similarly take place on the CYP3A4, CYP3A5 and MDR-1.
This information should be benefit on the pharmacologic
and organ transplantation worldwide.Conclusion
In the cytochrome P450 system, isoenzyme polymor-
phisms may play an important role in drug metabolism,
primarily in donor liver grafts with different genotypes
after liver transplantation. Genomic polymorphisms may
be mutant with a biogenetic phenomenon, and the main-
stream expression depends on the donor in the cyto-
chrome P450 system. Pyrosequencing may be a reliable
method to identify changes in polymorphisms after LDLT.
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